Hemoglobinopathy Treatment Market is anticipated to grow at a significant CAGR during the forecast period. The growth of the market is primarily attributed to a surge in the cases of hemoglobinopathies, as well as the public awareness of hemoglobin disorders. According to the World Health Organization, about 1.1% of the expecting parents globally are at the risk of having a child with hemoglobin disorder. Adding to this, a strong product pipeline aiming towards the treatment of hemoglobinopathies coupled with the constant endeavours from the market players and government in developing the new therapies for the treatment of hemoglobinopathies are projected to uplift the market.
Likewise, various government and private organizations led initiatives such as neonatal screening to detect the potential disorders are further projected to fuel the market growth. Along with the governmental programs, rising approvals for novel therapies from the regulatory bodies are expected to boost the market growth. For instance, in 2019, the FDA approved Reblozyl, Adakveo, Zynteglo, and Oxbryta for the treatment of haemoglobin disorders.
Some key players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., Celgene Corp. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for haemophilia A gene therapy. Such collaborations are further anticipated to drive market growth. Further, in December 2017, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated entered into a partnership to develop and commercialize novel gene-editing treatments for thalassemia using CRISPR/Cas9 technology.
To Request a Sample of our Report on Hemoglobinopathy Treatment Market: https://www.omrglobal.com/request-sample/hemoglobinopathy-treatment-market
Market Coverage
- The market number available for – 2020-2030
- Base year- 2022
- Forecast period- 2021-2030
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., Celgene Corp, among others.
A full Report of Hemoglobinopathy Treatment Market is Available @ https://www.omrglobal.com/industry-reports/hemoglobinopathy-treatment-market
Hemoglobinopathy Treatment Market by Segment
By Treatment
- Stem Cell Therapy
- Blood Transfusion,
- Iron Chelation Therapy,
- Others
By Application
- Thalassemia
- Sickle Cell Anaemia
- Others
Hemoglobinopathy Treatment Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hemoglobinopathy-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
